Inhibits vitamin K epoxide reductase (VKOR) → depletes reduced vitamin K → prevents γ-carboxylation of factors II, VII, IX, X + proteins C/S. Narrow therapeutic index + massive interaction list + dietary K variability → DOACs (apixaban, rivaroxaban) now preferred for non-valvular indications.
Half-Life & Elimination Curve (PO: 40h)
Plasma (PO)t½ Decay (40h)
0×t½0h100%(0.526 mg/L)
1×t½40h50%(0.263 mg/L)
2×t½3.3d25%(0.132 mg/L)
3×t½5d12.5%(65.8 µg/L)
4×t½6.7d6.3%(32.9 µg/L)
5×t½8.3d3.1%(16.4 µg/L)
Elimination t½40h (PO)
Rate Constant (ke)0.0173 h⁻¹
Time to Peak (Tmax)3.01h
Est. Peak (Cmax)0.526 mg/L
Clearance (CL)0.139 L/h
97% Washout (5×t½)8.3d
Dosing Guidelines
Oral (PO): Typical 4.67 mg (Range: 2–10 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 95% · Volume of Distribution (Vd): 8 L · Absorption (ka): 1.5 h⁻¹ (t½ka ≈ 28m) [PMID 18679669]